TXA127 Phase 2 Stroke Recovery Trial Begins

Boston-based biopharmaceutical firm, Constant Therapeutics LLC, has initiated a pivotal phase in its clinical research with the dosing of the first patient in a phase 2 trial for TXA127, a promising peptide therapy for ischemic stroke recovery. The study, which is a randomized, placebo-controlled, double-blind, and hybrid decentralized approach, aims to assess the safety and efficacy of the treatment in stroke survivors aged 18 to 85, who are between 6 to 24 months post-stroke. Over a span of three months, participants will receive the therapy as part of a clinical trial being held at Israel's Sheba Medical Center, in partnership with Sabar Health, which will facilitate home visits, with an anticipated enrollment of 50 patients.

The CEO of Constant Therapeutics, Rick Franklin, highlighted the significance of this trial, noting the absence of drugs specifically designed for chronic stroke treatment and the inherent challenges in conducting clinical trials for this patient demographic. He expressed gratitude for the collaborative efforts with Sabar Health and Sheba Medical Center, which have been instrumental in establishing the necessary infrastructure to address this significant medical gap.

TXA127, the lead compound of Constant Therapeutics, is derived from a naturally occurring peptide known as Angiotensin (1-7). This pharmaceutical formulation has demonstrated potential not only in aiding ischemic stroke recovery but also in treating various other conditions. In preclinical studies, TXA127 has shown therapeutic benefits in animal models for Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome, and Epidermolysis Bullosa, indicating its broad therapeutic potential.

Constant Therapeutics is a dedicated private company that focuses on developing treatments targeting the Alternative Renin-Angiotensin System, a key pathway in the body's regulation of blood pressure and fluid balance. The company's commitment to advancing TXA127 underscores its mission to provide innovative solutions for challenging medical conditions.

The commencement of the phase 2 trial represents a critical step forward in the quest to develop effective treatments for ischemic stroke recovery, offering hope to patients and their families who have long awaited such advancements. With the support of strategic partnerships and robust clinical trial design, Constant Therapeutics is poised to contribute meaningfully to the field of stroke recovery and beyond.